SEC Filing Summary: SIGA Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
Company: SIGA Technologies, Inc.
Filing Date: September 18, 2008
Reporting Period: Event date of September 18, 2008
Business Context: SIGA is a Delaware corporation focused on the development of ST-246, a potent, non-toxic inhibitor of orthopoxviruses currently in advanced development for regulatory approval.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific event and does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data for a reporting period.
- New Funding Received: $20 million
- Funding Source: National Institute of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health.
- Existing Contract Value: $16.5 million (supplemented by the new funding).
- Debt and Liquidity: The filing text does not provide a clear value for total debt, cash balances, or liquidity ratios.
Material Changes
The primary material change is the receipt of an additional $20 million in supplemental funding. This amount is intended to accelerate process development related to large-scale manufacturing and packaging of ST-246, as well as commercial-scale validation. This funding is provided by the Office of the Biomedical Advance Research and Development Authority, Department of Health and Human Services, to NIAID to advance biodefense products.
Outlook, Risks, and Management Commentary
Management Commentary: The company announced the funding via a press release (Exhibit 99.1) to highlight the acceleration of ST-246 development efforts.
Outlook: The additional capital is specifically earmarked to advance the drug toward regulatory approval through manufacturing and packaging validation.
Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the standard development phase of a biodefense product.
Key Facts for Investor Verification
- Verify the total cumulative funding received from NIAID ($16.5 million existing + $20 million new).
- Confirm the specific milestones for ST-246 manufacturing and packaging validation to be funded by this grant.
- Review the attached press release (Exhibit 99.1) for detailed terms of the agreement.
- Check subsequent filings for the impact of this funding on the company's cash runway and burn rate.